Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. (Q37838801)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author

Rocío García-Carbonero

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Eric Raymond

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Timothy Hobday

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Daniel Castellano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Diane Reidy-Lagunes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Alfredo Carrato

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

Cancer and Metastasis Reviews

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

30 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

19-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10555-011-9291-2

22 January 2020

exact match

0 references

cites work

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Regulation of angiogenesis by hypoxia: role of the HIF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Structure and function of VEGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Role of insulin-like growth factor-1R system in colorectal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

The insulin-like growth factor pathway in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Insulin-like growth factors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9291-2

10.1007/S10555-011-9291-2

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21308478%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference